This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Long-term Extension Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-Epileptic Drugs (AEDs)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Eisai Inc. ( Eisai Co., Ltd. )
ClinicalTrials.gov Identifier:
NCT00903786
First received: May 15, 2009
Last updated: March 17, 2017
Last verified: March 2017
May 15, 2009
March 17, 2017
June 17, 2009
August 8, 2016   (Final data collection date for primary outcome measure)
Number of patients with adverse events as a measure of safety [ Time Frame: 4 weeks, 8 weeks, 16 weeks and every 12 weeks till approval ]
Assessment of adverse events, laboratory examinations, vital signs, 12-lead electrocardiograms, and withdrawal questionnaires. [ Time Frame: 52 weeks after administration. ]
Complete list of historical versions of study NCT00903786 on ClinicalTrials.gov Archive Site
Evaluation of patient diaries for seizures [ Time Frame: 4 weeks, 8 weeks, 16 weeks and every 12 weeks till approval ]
Evaluation of patient diaries for seizures. [ Time Frame: 56 weeks. ]
Not Provided
Not Provided
 
A Long-term Extension Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-Epileptic Drugs (AEDs)
A Long-term Extension Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-Epileptic Drugs (AEDs)
The purpose of this trial is to investigate the safety and tolerability of perampanel in long- term treatment in the patients with refractory partial epilepsy (uncontrolled with other anti-epileptic drugs) who completed Week 10 of Phase II Study E2007-J081-231 study.
Not Provided
Interventional
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Refractory Partial Seizures
Drug: perampanel
Patients will receive the same oral dosage (2 mg up to 12 mg once daily before bedtime) as used in the maintenance period of Study 231.
Experimental: Perampanel 2 mg
Intervention: Drug: perampanel
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
21
October 31, 2016
August 8, 2016   (Final data collection date for primary outcome measure)

Inclusion criteria:

  1. Patients who consent to the study entry on their free will before starting any trial-related activities.
  2. Patients who participated in Study 231 and completed the required evaluation period (10 weeks).
  3. Patients who are certainly and voluntarily able to participate in this study and record their seizures by themselves or have family members or caregivers (or nurses, if hospitalized) record the seizures. Patients who wish to continue perampanel treatment and necessitate receiving the long- term administration judged by the investigator or sub-investigator.

Exclusion criteria:

  1. Pregnant or lactating women, women of child-bearing potential, women willing to become pregnant.
  2. Patients who are ineligible judged by the investigator or sub investigator in light of medical history or complication at enrollment in treatment period.
  3. Patients who operate heavy equipment or drive should not be recruited into the study.
  4. Patients who are ineligible for study entry judged by the investigator or sub-investigator.
Sexes Eligible for Study: All
20 Years to 64 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
Japan
 
 
NCT00903786
E2007-J081-233
Not Provided
Not Provided
Not Provided
Eisai Inc. ( Eisai Co., Ltd. )
Eisai Co., Ltd.
Not Provided
Study Director: Kazunori Saeki Neuroscience Clinical Development Section. JAC PCU. Eisai Co., Ltd.
Eisai Inc.
March 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP